Genmab and AbbVie Present New Epcoritamab Data at EHA 2023
Dr. Reid Merryman, MD, an attending physician in the Lymphoma Program at the Dana-Farber Cancer Institute discusses Genmab and AbbVie’s preliminary data from its ongoing phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab in patients across B-Cell lymphomas that were presented at the European Hematology Association’s (EHA) Annual Meeting 2023. Read the abstract here.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Cancer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Cancer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Cancer?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Dr. Merryman received his undergraduate degree from the University of Notre Dame and his medical degree from Harvard Medical School. He completed residency training in internal medicine at Brigham and Women’s Hospital and fellowship training in hematology and oncology at Dana-Farber/Partners Cancer Care. He is an attending physician in the Lymphoma Program at Dana-Farber Cancer Institute. His research focuses on the development of immune-based therapies for patients with lymphoma.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
